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Ubiquitin and ubiquitin-like (Ubl) protein modifica-
tions affect protein stability, activity, and localization,
but we still lack broad understanding of the functions
of Ubl modifications. We have profiled the protein
targets of ubiquitin and six additional Ubls in mitosis
using a functional assay that utilizes active mamma-
lian cell extracts and protein microarrays and identi-
fied 1,500 potential substrates; 80–200 protein
targets were exclusive to each Ubl. The network
structure is nonrandom, with most targets mapping
to a single Ubl. There are distinct molecular functions
for each Ubl, suggesting divergent biological roles.
Analysis of differential profiles between mitosis and
G1 highlighted a previously underappreciated role
for the Ubl, FAT10, in mitotic regulation. In addition
to its role as a resource for Ubl modifications, our
study provides a systematic approach to analyze
changes in posttranslational modifications at various
cellular states.INTRODUCTION
The number of different protein isoforms in the human proteome
is estimated to be about three orders of magnitude higher than
the number of genes. This diversity is largely due to posttransla-
tional modifications (PTMs). Among these modifications, the
ubiquitin-like (Ubl) molecule family appears to be very diverse
in function. The Ubls comprise a class of evolutionarily con-
served polypeptides that can be reversibly conjugated through
the formation of isopeptide bonds to lysine residues (mostly)
on proteins, where they regulate activity, stability, cellular local-
ization, and interaction with other proteins (Hochstrasser, 2009).
Ubiquitin and Ubl conjugation pathways have already been
implicated in human diseases, including numerous types of
cancer (Hoeller et al., 2006), viral diseases (Edelmann and Kess-
ler, 2008), and neurodegenerative disorders (Hattori andMizuno,
2004). However, most of our knowledge stems from studies
dedicated to ubiquitin and a couple of its homologs, namely
SUMO and NEDD8. More than a dozen Ubl family members
have been characterized to date, including the ones that1160 Cell 152, 1160–1172, February 28, 2013 ª2013 Elsevier Inc.we profile here: SUMO1, SUMO2/3, NEDD8, UFM1, FAT10,
and ISG15.
Though the Ubl proteins share only modest primary sequence
identity with ubiquitin (Figure 1A), they are closely related in
structure, and each, like ubiquitin, requires a multistep enzyme
cascade for attachment to a target protein. It is thought that
the Ubl modifiers use unique sets of the E1, E2, and E3 enzymes
and Ubl-specific proteases in this cascade. Although we are still
far from having a complete list of substrates for each Ubl, it is
already apparent that the targets of different Ubls are not always
exclusive. For instance, SUMO modification can antagonize
ubiquitylation and stabilize protein substrates at the same lysine
residue, both for PCNA (Papouli et al., 2005) and IkB (Lamsoul
et al., 2005). In another example, the ubiquitin E3 ligase RNF4
recognizes SUMOylated proteins and targets them to the pro-
teasome (Sun et al., 2007). Such crosstalk may be conserved
from yeast to humans; NEDD8 was shown to regulate the ubiq-
uitylation efficiency of cullin E3 ligases (Morimoto et al., 2000).
Though these are interesting examples, we do not knowwhether
there are general rules at work or even how common such cross-
talk is. With >500 genes that appear to be E3 ligases and >60
E2s in the human genome, the regulatory pathways involving
Ubl modifications could be of dizzying complexity. Linking
specific Ubls to their substrates is an essential first step in
understanding specificity and selectivity of Ubl modifications
and identifying the pathways in which they operate. However,
despite their growing importance, there are remarkably few
analytical tools available to analyze their behavior.
Traditional assays on single proteins often take years
before meaningful conclusions can be drawn, as was the
case for several important cell-cycle regulators targeted by
the anaphase-promoting complex, e.g., Securin, Geminin, and
Sororin. Though such approaches are important, they are often
too laborious to reach a coverage sufficient to reveal global
patterns of function. Although recent advances in mass spec-
trometry have dramatically improved our ability to detect some
modifications, it is still difficult to detect modifications that
are unstable and of low abundance. We recently established
a proteome-wide strategy based on functional concentrated
cell extracts to monitor systematic ubiquitylation (Merbl and
Kirschner, 2009). Applying this assay, we identified mitotic ubiq-
uitylation substrates of the anaphase-promoting complex (APC).
We revealed more than 100 potential APC targets. Of 16
previously known ubiquitylation targets in the assay, 11 were
Figure 1. Global Identification of Ubiquitin
and Ubl Targets in Mitosis
(A) Phylogenetic relationship of selected members
of the ubiquitin-like protein family. Branch lengths
are proportional to phylogenetic distances, and
the percent sequence similarity to ubiquitin is
given in parentheses. NS, not similar to ubiquitin
by standard BLAST search. Asterisks indicate
diubiquitin proteins (ISG15, FAT10) that have two
numbers for similarity representing each domain.
(B) Experimental design. Mitotic HeLa S3 cell
extracts were incubated on protein microarrays
with or without the addition of UBCH10, a protein
that abrogates the checkpoint arrest and allows
the extracts to proceed toward mitotic exit. Ubl
modifications on the spotted proteins are then
measured by labeling the arrays with Ubl-specific
antibodies, and fluorescently labeled secondary
antibodies are used to quantify the reactivity
profile of the 9,000 proteins on the array toward
each Ubl antibody.identified, indicating that the assay was reliable with a low false-
negative rate. This system offered a rapid, tractable and semi-
quantitative high-throughput system capable of monitoring
multiple modifications on thousands of proteins in parallel. The
assay makes use of the activity of cellular extracts under condi-
tions that are relatively close to those of the complex cellular
environment. It is highly reproducible and amenable to manipu-
lation (e.g., drugs, inhibitors), and it detects modifications
equally for low- and high-abundance proteins.
We have expanded our approach to provide a comprehensive
survey of the substrates of six additional Ubl modifiers (SUMO1,
SUMO2/3, NEDD8, FAT10, UFM1, and ISG15) in mitosis and toCell 152, 1160–1172, Fgenerate a Ubl interaction map. We
assayed those Ubls for which there
were good commercial antibodies avail-
able, excluding the autophagy-related
Ubls, whose activity might not be re-
flected in our in vitro system. The exten-
sive identification of substrates gives
us an idea not only of the degree to
which the Ubl proteins target related
substrates, but also information about
the pathways that they regulate. Finally,
we identified many putative Ubl targets
involved in mitotic regulation and
provided information about an under-
appreciated role for FAT10 in mitotic
progression.
RESULTS
Global Identification of Ubiquitin
and Ubl Targets in Mitosis
Concentrated cell extracts have been
used extensively to study cellular pro-
cesses, such as the cell cycle, nuclear
membrane assembly, and cytoskeletalregulation, and have provided insights into regulatory control at
the protein level. Recently, we applied such functional extracts
made from mammalian cells to protein microarrays with the
goal of assaying ubiquitylation in mitosis. The modification of
a subset of the proteins was revealed by specific antibodies
for ubiquitin, and the reactivity of the target protein can be calcu-
lated from the spot intensity (see Experimental Procedures for
image analysis and normalization). The activity of the extracts
allows for context-dependent interactions. In such cases, the
set of modifications is characteristic of the cellular state of the
extract. For APC, we were able to show that the assay is highly
sensitive (spanning more than four orders of magnitude ofebruary 28, 2013 ª2013 Elsevier Inc. 1161
reactivity signal) and highly reproducible (Merbl and Kirschner,
2009). Because this approach could in principle be applied to
any modification using the appropriate specific antibody, we
expanded our approach to other Ubls for which less is known
about their targets.
Here, we explore the role of several ubiquitin-like modifica-
tions (ubiquitin, SUMO2/3, NEDD8, FAT10, SUMO1, UFM1,
and ISG15) in mitotic regulation. For these seven modifications,
we profiled the modification state of 9,000 of proteins before
and after release from mitotic arrest (Figure 1B). These extracts
have been shown to promote full checkpoint arrest and APC inhi-
bition and to be relieved of that inhibition by UBCH10 (Reddy
et al., 2007). Extracts were applied to duplicate microarrays for
each modification under each of two conditions: ‘‘arrested’’
(blocked in mitosis with nocodazole) and ‘‘released’’ (released
from the checkpoint into anaphase/G1 by supplementing
UBCH10).
Defining a Ubl Modification Network
For each Ubl, we focused on highly reactive proteins defined as
having a specific reactivity greater than two standard deviations
above the mean (when normalized to the protein abundance on
the chip; see Experimental Procedures and Figure S1 available
online). All proteins passing these criteria have a reactivity that
is significantly higher than the background reactivity of negative
control spots (data not shown). Each Ubl reacted with 158–506
proteins above the threshold. We found 1,543 such target
proteins that are highly reactive to at least one of the Ubls (Table
S1). For ubiquitin, which is the most investigated protein in this
family, 70% of the targets that we identified were previously
described by others either in vitro or in vivo as ubiquitylation
substrates (see Table S2). Thus, the false-negative rate of the
assay is tolerably low.
From this broad view, we can ask several questions. Are
there general patterns of Ubl specificity across the proteome?
Specifically, are distinct pathways targeted by specific Ubls, or
are the modifications distributed among all biological pathways
and functions? Conversely, how much overlap exists between
the protein targets of the different Ubls? As a first step in our anal-
ysis, we characterized each reactive protein target’s interaction
with each of the seven Ubl modifications. Some proteins are
reactive to just oneUbl (e.g., RAD23A, which exhibited high reac-
tivity only toward ubiquitin), whereas others react with multiple
Ubls (e.g., IGF1R). Several examples of such interactions were
previously reported and are shown in Figure 2A (MITF [Murakami
and Arnheiter, 2005], CDKN1B [Carrano et al., 1999], IGF1R
[Girnita et al., 2003; Sehat et al., 2010], and RAD23A [Kumar
et al., 1999]). Among these, a few have been identified only
recently. Interestingly, the assay does not only recognize puta-
tive substrates, but also some of the enzymatic machinery for
each of the Ubl pathways (e.g., DCN1 [Kurz et al., 2008],
UBE2F [Huang et al., 2009], and UBE2Z [Aichem et al., 2010] in
the cases in wherein these enzymes were spotted on the array.
Several enzymes were associated with specific Ubl reactivities
for which we still do not know the underlying biology and thus
suggest open directions for investigation (see Table S1).
To identify global patterns of Ubl modifications, we mapped
the different targets for each Ubl into an interaction network1162 Cell 152, 1160–1172, February 28, 2013 ª2013 Elsevier Inc.(Figure 2B). The network consists of seven hubs corresponding
to the Ubls and multiple nodes representing each of the target
proteins. Edges between the hubs and nodes represent the
PTM interactions. The network reveals the interaction of the
different Ubls with their targets and their degree of specificity.
Most of the Ubl targets (65% of 1543) map just to a single Ubl
(Figure 2B, proteins assembled at the rim of the graph), whereas
the remaining targets (35%) map to at least two Ubls (proteins in
the center of the graph). Thus, most proteins are regulated
primarily by one Ubl modification but differed for the different
Ubls. For example, only 20% were unique to SUMO1, whereas
68% of FAT10 targets were unique to FAT10 (Figure 2C).
The Ubl Network Organization Features Both Exclusive
and Preferential Targeting of Substrates by Different
Ubls
The network (Figure 2B) reveals that a large number of target
proteins interact with multiple Ubls, with a few (2.6%) interact-
ing with five or more modifications (nodes in the center of the
network). This pattern suggests that there is considerable spec-
ificity in Ubl modification and raises the question of whether the
relatively few cases of multiple reactions on a single protein have
any functional significance or could merely be explained by
chance. To test whether this is the case, we generated 1,000
random permutations of the network that preserved the number
of edges from each hub and compared the resulting edge distri-
bution to the empirical data (Figure 3A). The analysis shows that
the number of unique targets (proteins targeted by only one Ubl)
was higher than would be expected by chance (65% observed
versus 52% ± 1.4% expected), and the fraction of doubly modi-
fied targets was much lower than expected by chance (19%
observed versus 34% ± 1% expected). Therefore, on average,
a protein modified by one Ubl is less likely to be targeted by
another.
The low abundance of doubly modified targets suggests that
certain Ubl combinations might be permitted though themajority
is not (Figure 3A). A pairwise correlation analysis of Ubl modifica-
tions (Figure 3B) confirmed that, indeed, many of the possible
double Ubl interactions are strongly suppressed (R% 0, shown
in black in Figure 3B). However, certain Ubl combinations are
overrepresented in the correlation map, indicating that certain
Ubls often cotarget the same substrates. We found a high corre-
lation between SUMO1 and SUMO2/3 targets (R = 0.58), as has
been previously suggested by others (Gocke et al., 2005; Matic
et al., 2008), as well as between UFM1 and FAT10 modifications
(R = 0.63).
The enrichment of the network for exclusive Ubl targets can
be studied by comparing specific Ubl reactivity combinations
to the predictions of randomized permutations (Figure 3C).
For single-targeted proteins, we found that only FAT10 and
UFM1 exhibited a higher frequency of exclusive targets
compared to random: 324 unique FAT10 targets were observed
when 161 were expected, and 202 UFM1 targets were observed
compared to 108 expected, suggesting that the functions
of the FAT10 and UFM1 systems are largely insulated from
the activity of other Ubls. The other Ubls (e.g., ubiquitin,
SUMO1, SUMO2/3) exhibited the same frequency of exclusive
targets as would be expected by chance, suggesting that
Figure 2. Defining a Ubl Modification
Network
(A) Examples of known Ubl targets and Ubl
pathway enzymes identified by the assay. A color
denotes reactivity toward that Ubl. The interac-
tions reported in the literature are cited in the text.
(B) The Ubl interaction network. Each protein is
connected to the Ubl with which it interacts.
Proteins that have multiple Ubls interactions are
shown at the center, and proteins that are reactive
exclusively with one Ubl are shown at the rim.
(C) The number of proteins targeted by each Ubl
showing specificity of the Ubl pathways. The
colored fractions represent the proportion of
targets reacting uniquely with each Ubl, whereas
the gray fractions represent the targets reactive
toward at least two Ubls.
See also Figure S1 and Tables S1 and S2.these parallel pathways evolved independently. Thus, the over-
representation of unique substrates is largely dominated by
UFM1 and FAT10.
Turning to proteins subject to multiple Ubl modifications, the
network exhibited a considerably higher frequency of such
proteins than would be expected by chance. Looking at specific
combinations of multiple Ubls (Figure 3C, red box), we find that
all except one of the possible patterns of targets with 6-Ubl
combination were enriched in comparison to randomized trials,
with 14 proteins, including RASL11B, DIRAS1, NEK4, PRKG2,
PRKCB, and IL15, undergoing six Ubl modifications when less
than one such instance is expected by chance.Cell 152, 1160–1172, FCellular and Functional
Classification of Ubl Targets
To ask whether the different Ubl path-
ways might be targeted to specific cate-
gories of proteins or associated with
distinct classes of biological processes,
we looked for overrepresented Gene
Ontology (GO) terms for Ubl target
protein annotations in the ‘‘Panther’’
database. For each Ubl, we calculated
the enrichment for GO terms identified
with its substrates. By comparing the
targets of each Ubl to the list of reactive
proteins only, we limit false-positive
enrichments that could arise from biases
in the representation of protein subsets
on the chip. Figures 4A and 4B present
a subset of the molecular functions and
biological processes related to the
targets of each Ubl; each column repre-
sents one Ubl (enriched terms are
colored; see Table S3 for a full list).
As the assay made use of mitotic
extracts, we expected to find enrichment
for mitosis-related annotations. Indeed,
the only overrepresented categories in
the cell cycle were mitosis and cytoki-nesis, (Figure 4B). As a further validation, we found that known
and well-characterized biological functions of ubiquitin and
SUMO were enriched (Figure 4A). For example, ubiquitylation
targets are the only ones enriched for the ubiquitin ligase activity
term, with numerous targets categorized as E3 ligases, or RING
finger proteins. In addition, SUMO1 and SUMO2/3 targets are
uniquely enriched for transcriptional-related terms and DNA
binding corresponding to their established role (Gill, 2005;
Girdwood et al., 2004). Interestingly, the assay also suggested
a class of translation initiation factors and RNA binding targeted
by the ISG15 modification. Previous work suggested that ISG15
modification is involved in translation control (Okumura et al.,ebruary 28, 2013 ª2013 Elsevier Inc. 1163
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Figure 3. The Ubl Network Features Both Exclusive and Preferential Targeting of Substrates by Different Ubls
(A) Comparison of observed distribution of Ubl reactivities with expected distribution for a random Ubl network. Each of the colored lines represents the
calculated frequency from 1,000 random network simulations showing exclusivity overrepresentation at n = 1 (targets of only one Ubl) and underrepresentation of
targets with two (n = 2) or three Ubl (n = 3) reactivities. The black line represents the observed frequencies in the network.
(B) Correlation analysis of Ubl profiles. Correlation coefficients between each of the Ubl reactivity profiles with all other microarrays reveal similarity among
SUMO1 and SUMO2/3 targets as well as among FAT10 and UFM1 targets. Each square shows the correlation coefficient (R) between two microarray
profiles, with four microarrays per Ubl. Black signifies no correlation or anticorrelation. Microarrays are grouped by their correlation (k-nearest neighbor
clustering).
(C) Ratio of observed versus expected frequencies of Ubl targets for each possible Ubl combination. The ratio represents the observed underrepresentation and
overrepresentation of certain Ubl combinations when compared to a permutated network. Each Ubl combination is color coded according to the specific pattern
of Ubl reactivity at the top.2007) and mainly targets newly synthesized proteins (Durfee
et al., 2010) of both human and viral origin. A recent paper sug-
gested a role for secreted ISG15 as a cytokine inducing IFN-g
production, which is key in the etiology of mycobacterial disease
(Bogunovic et al., 2012). Thus, it appears that ISG15 may exert
its functions by directly targeting intracellular proteins, affecting
the expression of IFN-g target genes by acting as a secreted
factor. Our putative ISG15 targets involved in translation initia-
tion suggest that the extract system may be suitable for detec-
tion of ISG15 substrates. Our results suggest a role for ISG15
targets in various signaling pathways (Table S3 and Figure S3)
and propose a few potential E3 ligases that may be involved in
ISG15 conjugation.1164 Cell 152, 1160–1172, February 28, 2013 ª2013 Elsevier Inc.Other findings from our analysis include the observations that
UFM1 targets are enriched in transmembrane transporters, ion
channels, and cytokine receptors and that FAT10 targets are
enriched for SNAP receptors, proteins related to extracellular
matrix activity, and DNA helicases. These potential targets await
in vivo validation. Notably, consistent with the wide range of
protein targets and biological processes that ubiquitin is known
to be involved in, we could not identify any unique enrichment
(i.e., not shared by other Ubls) defined by the molecular function
of ubiquitin targets except for the ligase activity mentioned
above. NEDD8, whose main function is to modulate E3 ligase
ubiquitylation activity, also did not show unique functional
enrichment.
Figure 4. Cellular and Functional Classification of Ubl Targets
(A) Enrichment analyses of ‘‘molecular functions’’ among Ubl targets, assessed by overrepresentation of Gene Ontology (GO) terms for the targets of each Ubl.
Terms discussed in the text appear in red.
(B) Same analysis as in (A) but for the ‘‘biological processes’’ annotations.
(C) Detailed breakdown of the subset of kinases in the network and their Ubl specificities (color-coded lines), showing an extensive crosstalk between kinases and
different Ubl modifiers.
See Figure S2A for a higher resolution of this image with protein names. Also see Figure S3 and Table S3.Kinases are especially enriched in the set of Ubl targets
(Figure 4A, bottom row). Specifically, SUMO1 and SUMO2/3
together targeted 68% of the kinases (Figures 4C and S2A) in
our network. Among these, we found kinases associated with
Wnt-signaling pathway, MAPK-signaling pathway, and other
pathways related to cancer (Figure 4D; see Figure S3 for a fulllist) as well as 20 known mitotic kinases. Indeed, we were able
to confirm in vitro the SUMOylation of Polo-like kinase 1 (PLK1)
and cyclin-dependent kinase-1 (CDK1) as well as other kinases
(Figure S2B). Consistent with our results, recent studies have
identified both AURKB (Ban et al., 2011; Ferna´ndez-Miranda
et al., 2010) and CDK1 (Golebiowski et al., 2009) as SUMOCell 152, 1160–1172, February 28, 2013 ª2013 Elsevier Inc. 1165
targets in vivo. In addition, a recent study also suggested
a SUMO-modulated protein phosphorylation regulation, based
onMSanalysis (Yao et al., 2011). Although the biological function
of these modifications is not yet clear, SUMOylation has been
proposed to have both promoting and inhibitory effects on
kinase activity (Yang and Sharrocks, 2006). These findings
emphasize the possibility of crosstalk between the SUMOylation
and phosphorylation pathways, opening a significant area for
further investigation.
Many of the Ubls are implicated in a common set of biological
processes (Figure 4B) that include cell-cycle regulation, apo-
ptosis, angiogenesis, cell adhesion, and embryonic develop-
ment. FAT10 and UFM1 are the exceptions: FAT10 targets
were overrepresented in peroxisomal transport, lipid metabolic
process, and cellular calcium homeostasis, whereas UFM1
targets were implicated in pathways classified as endocytosis,
hemopoeisis, neurotransmitter secretion, and lipid transport.
Interestingly, both FAT10 and UFM1 appear to have enrichment
for targets involved in antigen presentation via MHC II, suggest-
ing that both may be involved in immune regulation. Yet both
FAT10 and UFM1 still have a significant number of targets
in the mitosis/cytokinesis pathways. For example, 27 of the
proteins modified by FAT10 were cell-cycle regulators, 19 of
which were mitosis related. Taken together, our results suggest
that the Ubl pathways evolved to regulate a wide range of cellular
and physiological processes. Each Ubl has some level of
discernible specialization, but they all appear to regulatemultiple
tasks in the cell.
Differential Regulation of FAT10 on Release from
Mitotic Arrest
By comparing the modifications at prometaphase with those at
anaphase/G1, we can assess the activity of Ubls at this specific
transition. To detect changes in Ubl modifications under condi-
tions that minimized variation in the extracts, we compared a
nocodazole-arrested HeLa cell extract (checkpoint arrested,
denoted as ‘‘arrested’’) with the same extract supplemented
with the E2 enzyme UBCH10, which relieves mitotic arrest
(denoted as ‘‘released’’) and drives the cell into anaphase and
G1 (Reddy et al., 2007). The reactivity level of each protein
toward each of the Ubls was calculated for these two conditions,
using two microarrays per condition. An ANOVA test that was
performed for the reactivity of each protein under these condi-
tions (whose p values were corrected using Storey’s false
discovery rate method [Storey et al., 2007]) showed that the
reactivity for both ubiquitin and FAT10 had the most significant
changes (q value < 0.1) upon release from the arrested into the
released state (Figure 5A).
We were surprised by changes in FAT10, whose role in mitosis
has been little studied. Figure 5B depicts examples of FAT10
reactivity levels for several proteins under the two conditions.
Our data identifiedMAD2 as a highly reactive substrate, as previ-
ously reported (Liu et al., 1999). However, its level was not signif-
icantly different in the two conditions. Most of the statistically
significant changes in FAT10 level were dramatic, mostly
decreasing two to three orders of magnitude (Figure 5C, blue
dots). This is in contrast to the significant increase in ubiquityla-
tion at the metaphase-anaphase transition, as reported earlier.1166 Cell 152, 1160–1172, February 28, 2013 ª2013 Elsevier Inc.The striking effect on FATylation could not be explained by the
variability of the assay (Figure 5C, orange dots) and was similar
with different detection antibodies (Figure S4A). Washing with
stringent conditions (3 3 0.5% SDS) did not alter our results
significantly, suggesting that most of the interactions that we
detect represent covalent FAT10 conjugation (Figure S4B). 106
proteins showed a significant change in FAT10 reactivity—either
an increase (30 proteins) or a decrease (76 proteins) between the
arrested and released states (q < 0.002; Figures 5C and 5E).
Differential FAT10 Targets Are Involved in Cell-Cycle
Regulation and Mitotic Progression
Among the proteins that showed the most striking change in
FAT10 were a subset mapped onto a known cell-cycle interac-
tion network (e.g., Securin, CUL1, SEPT6 and CDK3; see Fig-
ure 5D). Immunofluorescence showed that both FAT10 and
UBE2Z, the only known E2-conjugating enzyme for the FAT10
pathway, were ubiquitously expressed in mitosis (Figures S5A
and S5B). We found global changes of FAT10 species at
the time of mitosis (Figure 6A). The level of UBE2Z was high
during G2/M and dropped precipitously at the metaphase/
anaphase transition, along with Securin (Figure 6A), consistent
with the dramatic reduction in FATylation signals upon release
from nocodazole arrest (see Figure S5C for cell-cycle analysis).
The level of UBE2Z is regulated by the spindle checkpoint, as
UBE2Z was completely stable for 15 hr in cells released from
the thymidine block into nocodazole (Figure S5D). Thus, the
timing of the degradation of UBE2Z suggests that it is required
for the mitotic checkpoint and that its degradation may be regu-
lated in an APC-dependent manner.
When we compared the list of targets that showed significant
FAT10 changes to a database of phenotypic outcomes based on
a genome-wide RNA interference screen (‘‘Mitocheck Consor-
tium’’ [Neumann et al., 2010]), we found eight of our candidates
to have a mitotic phenotype (delay) upon knockdown and
two additional genes to have a death phenotype (Figure S6A).
Thus, among the 106 differentially regulated targets, roughly
10% were already shown to have mitotic defects upon inhibition
in vivo. We were further able to detect the in vitro FATylation of
four out of six proteins that we tested from the predicted
FAT10 substrate list (Table S1). Both TP53 and UBE2Z, which
were used as positive controls, were modified in vitro as well
(Figure S6B). We were also able to detect FATylation of four
additional proteins by immunoprecipitation (Figure S6C).
Notwithstanding the importance of establishing the role of
the FATylted substrates in vivo, the decrease in FAT10 modifi-
cation on exiting metaphase itself suggested that the FAT10
pathway might have some regulatory role in mitotic progression.
Inhibition of the FAT10 Pathway Leads to Prolonged
Mitotic Arrest and Cell Death
To look for a regulatory role for FAT10 in mitosis, we inhibited
FATylation via either a knockdown of FAT10 or knockdown of
its E2-conjugating enzyme, UBE2Z. We transfected HeLa cells
either with siRNA against FAT10 or UBE2Z or with control siRNA,
and we allowed the cells to grow for 72 hr (Figure S7). In both
knockdowns, but not in the control, there was a substantial
increase in the duration of mitosis, eventually leading to cell
Figure 5. FAT10 Targets Are Involved in Cell-Cycle Regulation and Mitotic Progression
(A) Signal intensity of FATylated protein targets was measured under nocodazole arrest and upon release from mitotic arrest. Values under the two conditions
were compared using ANOVA, and the resulting p values were plotted (ascending order) for each Ubl separately. The two dotted lines indicate p value cutoff
(legend continued on next page)
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death (Figure S7 and Movies S1, S2, and S3). When we quanti-
fied the average duration in mitosis (Figure 6B), we found that
cells stayed in mitosis at least twice as long, on average, as
controls (5.93 ± 1.96 and 8.48 ± 2.58 hr for UBE2Z and FAT10
knockdowns, respectively), when compared to cells transfected
with control siRNA (2 ± 0.8 hr).
We cannot at this point assess whether the effects that we
observe are due to FAT10 conjugation or whether FAT10 on
its own or through binding interactions exerts these effects.
However, our results strongly suggest that FAT10 is involved in
mitotic regulation.
Previous studies noted that FAT10 overexpression (Canaan
et al., 2006; Raasi et al., 2001; Ross et al., 2006; Snyder et al.,
2009) and UBE2Z overexpression (Aichem et al., 2010; Park
et al., 2007) may lead to apoptosis. However, these studies
did not link cell death to the cell-cycle or mitosis. We found
that either the inhibition of FAT10 or UBE2Z extended mitotic
arrest and triggered cell death (Figures 6C and 6D). The
UBE2Z knockdown effect may be more pronounced, as the
death occurred earlier than in the FAT10 knockdown, where
cells arrested in mitosis for up to 13 hr before dying. Because
UBE2Z performs upstream to FAT10 and was shown to also
mediate ubiquitylation, its loss may be more broadly deleterious
to the cell. It is interesting to note that, under the FAT10 knock-
down conditions, all of the cells that died did so only after
prolonged arrest in mitosis. Finally, by blocking the activation
of the canonical apoptosis pathway via BCL2 overexpression
(McGill et al., 2002), the death phenotype could be suppressed
(data not shown).
DISCUSSION
While we know that the landscape of the proteome is largely
controlled by PTM regulation, some of the most important ques-
tions about PTM function remain. With relatively few E3s identi-
fied for the Ubls, how is the timing and substrate specificity of
these modifying activities regulated? Might the modification of
one Ubl inhibitor activate another Ubl? Is there some subfunc-
tionalization of the various Ubl modifications either related to bio-
logical activity (kinases versus proteases), to specific pathway
(e.g., Hedgehog versus cytokine), or to some general type of
overall biological function (transcription versus metabolism)?
The methodologies for addressing such questions on a pro-
teome-wide scale are still limiting. In this study, we have profiled
the PTMs for one cell type at the metaphase-anaphase transi-
tion. Although this choice reflects only a subset of cellular ac-
tivities, mitosis involves many cellular processes that undergolevels of 0.1 and 0.05 (orange and brown, respectively). The y axis denotes the
differential reactivity.
(B) An example of duplicate spots of a FAT10-modified substrate under the two
(C) Signal intensity of two biological replicates was compared to the signal inten
intensity (log scale) under nocodazole arrest. (y axis) Replicate biological condition
diagonal represent the proteins that were differentially modified by FAT10.
(D) Potential targets that mapped onto a known interaction network for cell-cycle
release from the mitotic arrest. Black names are interactors in the network that w
(E) Proteins showing the highest differential modification under the two conditions
standardized to have a mean reactivity of 0 and SD of 1.
See also Figure S4.
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the inhibition of most transcriptional activity during mitosis,
much of the regulatory burden is born by PTMs. Many modifica-
tions required for the proper progression of mitosis have been
characterized to date, and they include phosphorylation, acety-
lation, ubiquitylation, and SUMOylation. Although this is already
an impressive list, these modifications have usually been identi-
fied in an ad hoc manner from the study of individual proteins.
Our strategy for global PTM profiling in mammalian cells is
broadly applicable. It requires only the appropriate antibodies
or direct labeling of the small modifier itself.
Most proteins targeted by members of the Ubl group (65%)
were modified by a specific Ubl; there are between 80 and
200 of these targets unique to each Ubl. However, the 35% of
targets subject to modification by multiple Ubls may signify
especially interesting regulatory processes. One pattern that
emerged from the network is that the Ubl pathways appear
largely independent of each other despite some potential cross-
talk between them. As outliers, the FAT10 and UFM1 pathways
were insular in their choice of targets, suggesting that these
pathways may have more specialized uses. It was a concern of
ours that, given the similar chemistry of the Ubl modification
reactions, there could be an appreciable background rate of
nonenzymatic coupling of the Ubls to target proteins, and this
would generate strong overlap in the Ubl targets. This turned
out not to be the case. We found instead clear specificity in the
choice of targets for the different Ubls. The sparseness of modi-
fication and the statistically few examples of overlap suggest
that the examples for which we did find overlap might be real
and of interest. Multiple targeting is not a simple expectation of
statistical overlap of independent events.
As with any high-throughput approach, the results reported
here will require additional validation using more directed exper-
iments. Though it is impossible to completely verify the Ubl
network that we generated, we found that, among the 1,543
substrates identified, between 200 and 500 interactions were
previously documented in the literature. It is hard to give an exact
number for the true positive rate, as it depends on the criteria by
which an interaction is defined. For example, the assessment
varies depending on whether target protein homologs in dif-
ferent species are considered. In addition, themethods by which
the modifications were identified (e.g., MS) and the nature of the
interactions (e.g., immunoprecipitation under denaturing condi-
tions versus yeast two-hybrid) may vary between different
studies.
Our analysis of differential Ubl modification profiles upon
release from nocodazole arrest, however, is largely protectedcumulative number of target proteins that showed the stated significance in
conditions, showing differences in reactivity.
sity under the two different conditions for each protein. (x axis) FAT10 signal
s (orange) or upon release from nocodazole arrest (blue). Dots that are off of the
regulation. Color denotes increased (red) or decreased (blue) reactivity upon
ere not targeted by FAT10.
(106) were clustered based on similarity. Signal intensity for each protein was
Figure 6. Inhibition of the FAT10 Pathway Using RNA Interference Leads to Mitotic Arrest and Cell Death
(A) FAT10, Ube2z, and Securin protein levels during cell-cycle progression. Samples were taken at the indicated time points (see Figure S5C for FACS analysis).
(B) The duration of mitosis was quantified from time-lapse movies. Cells treated with siRNA for Ube2z or FAT10 spent a significantly longer time in mitosis
(p < 0.05) when compared to cells treated with control siRNA. Error bars depict mean ±SE.
(C) A representative cell (n > 30 per condition) undergoing mitosis for each of the different condition (siFAT10, siUbe2z, and siControl) is presented.
(D) Quantitation of the percentage of cells in interphase (left) andmitosis (middle) and percentage of dead cells (right) in each of the conditions during the course of
the experiment.
Error bars depict mean ±SE. See also Figures S5, S6, and S7, as well as Movies S1, S2, and S3.from false hits that would affect each spot for each condition in
the same way. In this case, differences between the arrested
and released conditionsmay bemeaningful, evenwhen absolute
measurements are not completely accurate. All but two Ubl
pathways altered some of their targets during mitosis, sug-
gesting that more PTMs may be involved in mitotic regulation
than previously thought. Surprisingly, we found that FAT10, an
under-investigated modification pathway, exhibited the most
dramatic changes in signal intensity of modified proteins. Ubiq-
uitin, which has already been widely investigated for its role inregulating the metaphase-anaphase transition, had the second
highest change upon release from mitotic arrest.
In our analysis, we found that the reactivity pattern of FAT10
was strikingly different than that of ubiquitin in the metaphase-
anaphase transition. While the polyubiquitylation signal in-
creased strongly, the FAT10 signal decreased for 76 out of 106
targets. Of these, at least 10% are presumably important in
mitosis, as judged by the fact that knockdowns by RNA interfer-
ence (RNAi) caused mitotic defects or death. In support of the
importance of FAT10 in mitosis, we showed that inhibiting theCell 152, 1160–1172, February 28, 2013 ª2013 Elsevier Inc. 1169
pathway by knocking down FAT10 or its E2-conjugating enzyme
(UBE2Z) resulted in a prolonged mitotic arrest followed by cell
death. Although UBE2Z overexpression was shown previously
to lead to apoptosis, it was not linked to defects in mitosis
(Park et al., 2007).
Our observations of significantly higher FATylation signal
under nocodazole arrest together with the decrease of UBE2Z
levels at the end of mitosis provides a clue for how Ube2z
functions in mitotic exit. However, though UBE2Z is the only
known E2-conjugating enzyme for the FAT10 pathway, it is
also able to conjugate ubiquitin (Aichem et al., 2010; Jin
et al., 2007). Thus, Ube2z may regulate both ubiquitylation and
FATylation events in mitosis. Of potential regulatory interest
is that, among the FAT10 substrates, were regulators of G-
protein-signaling family members (RGS1, RGS4, RGS5,
RGS10, and RGS14), two of which were recently identified as
ubiquitylated UBE2Z substrates (Lee et al., 2011). However,
because UBE2Z can conjugate ubiquitin as well as FAT10, it is
not clear whether the RGS family members may also be regu-
lated via the FAT10 pathway in vivo.
Although FAT10 was discovered more than a decade ago, our
knowledge of its biological function is limited. FAT10, also known
as diubiquitin, has been suggested to be the only Ubl modifier
that might target proteins for degradation through conjugation
(Hipp et al., 2005; Pelzer and Groettrup, 2010). However, few
in vivo covalent substrates of FAT10 have been identified to
date (Aichem et al., 2012), including UBE2Z (in cis) and TP53
(Aichem et al., 2010; Li et al., 2011). Thus, it is still unclear
whether FAT10 acts as part of a signaling pathway or funnels
proteins to the proteasome for degradation. In addition, it was
recently shown that FAT10 itself is rapidly degraded by the ubiq-
uitin-proteasome system (Buchsbaum et al., 2012). The known
phenotypes of FAT10 misregulation tell us little about its targets.
FAT10 has been implicated in at least three aspects of car-
cinogenesis and mitosis: (1) overexpression increases mitotic
nondisjunction and chromosome instability (Ren et al., 2006),
(2) FAT10 is upregulated in several epithelial tumors (Lee et al.,
2003; Qing et al., 2011; Zhang et al., 2006), and (3) overexpres-
sion of FAT10 causes apoptotic cell death (Raasi et al., 2001;
Ross et al., 2006; Snyder et al., 2009). Finally, in one molecular
study, overexpression of FAT10 greatly reduced the binding of
MAD2, to kinetochores (Liu et al., 1999), during prometaphase.
These observations provide evidence for a link between FAT10
and mitosis. However, a key role for FAT10 in mitosis regulation
might seem surprising, as FAT10 knockout mice are viable
(Canaan et al., 2006). This expectation is not borne out for other
seemingly critical cell-cycle regulators—such as cyclin D1, D2,
D3; cyclin E1 and E2; and CDK2, E2F, and p27—suggesting
that compensation in mitosis may be common.
That FAT10, a vertebrate-specific protein, has an important
function in mitosis may also seem surprising on evolutionary
grounds. Early studies suggested a potential role for FAT10 in
adaptive immunity, another process that arose in the vertebrate
clade. Taken together, we propose that FAT10 may function in
mitosis only in a context-specific manner such as specific cell
types or under certain conditions (e.g., inflammation). We might
imagine that the role of FAT10 in mitosis is not unlike adaptive
immunity—both systems grafted onto more ancient pathways.1170 Cell 152, 1160–1172, February 28, 2013 ª2013 Elsevier Inc.If that is true, there may be therapeutic opportunities for FAT10
in proliferative diseases that are quite distinct from other mitotic
targets.
EXPERIMENTAL PROCEDURES
Tissue Culture and Cell Synchronization
For extract preparation, HeLa S3 cells were synchronized in prometaphase by
treatment with nocodazole and prepared as previously described. (Merbl and
Kirschner, 2009; Rape and Kirschner, 2004; Storey et al., 2007). PTM profiling
and microarray scanning were done as previously described (see Extended
Experimental Procedures).
Ube2z and FAT10 siRNA
To deplete FAT10 and Ube2z, Dharmacon siGENOME SMARTpool against
FAT10 or Ube2z (M-008266-03 and M-008596-02, respectively) were used
in all experiments at a final concentration of 20 nM. As a control Dharmacon
siGENOME nontargeting siRNA pools #1 and #2 were used at 20 nM
(D-001206-13-05 and D-001206-14-05, respectively). siRNA transfection
was performed using Oligofectamine (Invitrogen) according to the manufac-
turer’s instructions. Cells were transfected for 48–72 hr depending on the
experiment and collected for analysis by western blot and real-time PCR or fol-
lowed by time-lapse microscopy. We note that the observed phenotype was
dependent on a high knockdown efficiency.
Real-Time PCR Analysis
To estimate the mRNA expression of FAT10 and Ube2z in cells treated
with RNAi, real-time PCR analysis was performed using TaqMan probes
Hs00225039, Hs00197374, and 4333476 for Ube2z, FAT10, and GAPDH,
respectively (Applied Biosystems). FAT10 and Ube2z levels were normalized
by the level of GAPDH in each sample. mRNA levels were then compared to
the mRNA levels in cells transfected with nontargeting siRNA (control).
Microscopy and Time-Lapse Imaging
Cells were seeded in glass-bottom plates (MatTek) in CO2-independent
medium (Invitrogen) supplemented with 10 FBS, 100 U/ml penicillin, and
100mg/ml streptomycin. For fluorescent time-lapse imaging, cellswere seeded
in phenol red-free CO2-independent medium (Invitrogen). Image acquisition
was performed using Nikon TE2000 automated inverted microscope with a
203 objective enclosed in a humidified incubation chamber maintained at
37C. Images were collected every 15 min using a motorized stage. Images
were viewed and analyzed using MetaMorph software (Molecular Dynamics).
In Vitro SUMOylation
E1 (250 nM) and E2 (0.5 uM) enzymes were added to a S35 radioactively
labeled substrate (TNT Quick Coupled Transcription/Translation; Promega)
with 10 uM recombinant SUMO1, SUMO2, or SUMO3. The reaction was sup-
plemented with energy mix and allowed to run in room temperature for 2 hr. As
a negative control, the same reaction is performed without the addition of the
E1 enzyme and ran for the same amount of time (the right lane of each gel).
Reactions are stopped by addition of sample buffer containing 5% b-mercap-
toethanol. To identify modified substrates, the samples were analyzed by
SDS-PAGE and phosphorimaging.
In Vitro FATylation
UBA6 (250 nM), UBE2Z (0.5 uM), and FAT10 (10 uM) were added to S35 radio-
actively labeled substrate (TNT Quick Coupled Transcription/Translation;
Promega). The reaction was supplemented with energy mix and allowed to
run for 1 hr at 30C. As a negative control, the same reaction is performed
without the addition of FAT10 and ran for the same amount of time. Reactions
are stopped by addition of sample buffer containing 5% b-mercaptoethanol.
ACCESSION NUMBERS
Official gene symbol and the relevant RefSeq or Gene Bank accession
numbers are presented for the proteins in this paper (see Table S1).
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